DERL3 functions as a tumor suppressor in gastric cancer

BACKGROUND Gastric cancer is a common malignant tumor in the clinic with a high mortality rate, ranking the first among malignant tumors of the digestive system. Early gastric cancer exhibits no specific clinical symptoms and signs, and most of the patients were diagnosed as advanced gastric cancer. The prognosis is poor, and the 5-year overall survival rate is still lower than 30%, seriously threatening people's life and health. However, the pathogenesis of gastric cancer is still unclear. METHODS This study aimed to identify methylated differentially expressed genes in gastric cancer and to study the cellular functions and pathways that may be involved in its regulation, as well as the biological functions of key methylated differentially expressed genes. The gene expression data set and methylation data set of gastric cancer genes based on TCGA were analyzed to identify prognostic methylated genes. RESULTS This study showed that the methylation of the DERL3 promoter was correlated with the clinical analysis of tumors. Further studies were conducted on genes co-expressed with DERL3, whose functions and pathways to inhibit gastric cancer were adaptive immune response, T cell activation, immune response-regulating pathway, cell surface on molecules, and natural killer cell-mediated cytotoxicity. Finally, cell proliferation assay, cell scratch assay, and cell invasion assay confirmed that DERL3 as a tumor suppressor gene inhibited the malignant evolution of gastric cancer. CONCLUSIONS The analysis of key methylated differentially expressed genes helped elucidate the epigenetic regulation mechanism in the development of gastric cancer. DERL3, as a methylation biomarker, has a predictive and prognostic value in the accurate diagnosis and treatment of gastric cancer and provides potential targets for the precision treatment of gastric cancer. TRIAL REGISTRATION Not applicable.

[1]  R. Kaufman,et al.  Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation , 2006, The Journal of cell biology.

[2]  Li Lin,et al.  Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. , 2017, Cancer letters.

[3]  A. Taddei,et al.  Gastric cancer and the epoch of immunotherapy approaches. , 2015, World journal of gastroenterology.

[4]  Honggang Zhou,et al.  Salvianolic acid A targeting the transgelin-actin complex to enhance vasoconstriction , 2018, EBioMedicine.

[5]  Hongbo Zhao,et al.  Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy , 2018, Cancer management and research.

[6]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[7]  Meilin Wang,et al.  Hypermethylation of EIF4E promoter is associated with early onset of gastric cancer , 2018, Carcinogenesis.

[8]  Honggang Zhou,et al.  Oleanolic Acid Inhibits Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization , 2018, Molecular Cancer Therapeutics.

[9]  Yuan Yuan,et al.  Bioinformatics-Based Identification of Methylated-Differentially Expressed Genes and Related Pathways in Gastric Cancer , 2017, Digestive Diseases and Sciences.

[10]  Chang-ming Huang,et al.  Evaluation of the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for Gastric Cancer: An Analysis of 7371 Patients in the SEER Database , 2019, Gastroenterology research and practice.

[11]  Huanming Yang,et al.  Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating aberrant hypermethylation of promoter CpG islands in cancer cells. , 2014, Genomics.

[12]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[13]  Ye Zhang,et al.  Midkine positively regulates the proliferation of human gastric cancer cells. , 2009, Cancer letters.

[14]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[15]  T. Ushijima,et al.  Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. , 2006, Cancer research.